{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:40:13Z","timestamp":1792428013314,"version":"4.5.0"},"reference-count":50,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP17K10238"],"award-info":[{"award-number":["JP17K10238"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alopecia areata (AA) is regarded as a tissue-specific and cell-mediated autoimmune disorder. Regarding the cytokine balance, AA has been considered a type 1 inflammatory disease. On the other hand, AA often complicates atopic dermatitis (AD) and AD is regarded as type 2 inflammatory disease. However, the immunological aspects of AA in relation to AD are still poorly understood. Therefore, we aim to clarify the immunological properties of AD-associated AA. In this study, we performed comparative analysis of the expression of intracytoplasmic cytokines (IFN-\u03b3, IL-4, and IL-13), chemokine receptors (CXCR3 and CCR4) in peripheral blood which were taken from healthy controls, non-atopic AA patients, AA patients with extrinsic AD, and AA patients with intrinsic AD by flowcytometric analysis. We also compared the scalp skin samples taken from AA patients with extrinsic AD before and after treatment with dupilumab. In non-atopic AA patients, the ratios of CD4+IFN-\u03b3+ cells to CD4+IL-4+ cells and CD4+IFN-\u03b3+ cells to CD4+IL-13+ cells were higher than those in AA patients with extrinsic AD. Meanwhile, the ratio of CD8+IFN-\u03b3+ cells to CD8+IL-13+ cells was significantly higher in the non-atopic AA than in the healthy controls. In AA patients with extrinsic AD, the skin AA lesion showed dense infiltration of not only CXCR3+ cells but also CCR4+ cells around hair bulb before dupilumab treatment. However, after the treatment, the number of CXCR3+ cells had no remarkable change while the number of CCR4+ cells significantly decreased. These results indicate that the immunological condition of AA may be different between atopic and non-atopic patients and between extrinsic and intrinsic AD patients. Our study provides an important notion that type 2 immunity may participate in the development of AA in extrinsic AD patients. It may be considered that the immunological state of non-atopic AA is different from that of atopic AA.<\/jats:p>","DOI":"10.3390\/ijms22052618","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T05:03:15Z","timestamp":1614920595000},"page":"2618","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata"],"prefix":"10.3390","volume":"22","author":[{"given":"Reiko","family":"Kageyama","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Hanai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Seirei Hamamatsu General Hospital, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3553-796X","authenticated-orcid":false,"given":"Shinsuke","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Fujiyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Tokura","sequence":"additional","affiliation":[{"name":"Department of Cellular &amp; Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0002-9440(10)63151-3","article-title":"Collapse and resto-ration of MHC class-I-dependent immune privilege: Exploiting the human hair follicle as a model","volume":"164","author":"Ito","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1087-0024.2003.00807.x","article-title":"The hair follicle and immune privilege","volume":"8","author":"Paus","year":"2003","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5114\/ceji.2020.101264","article-title":"Immunology of alopecia areata","volume":"45","author":"Rudnicka","year":"2020","journal-title":"Cent. Eur. J. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/exd.12209","article-title":"What causes alopecia areata?","volume":"22","author":"McElwe","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.0022-202X.2004.23580.x","article-title":"Alopecia areata induced in C3H\/HeJ mice by interferon-gamma: Evidence for loss of immune privilege","volume":"124","author":"Gilhar","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2353\/ajpath.2008.061249","article-title":"Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a C3H\/HeJ mouse model","volume":"172","author":"Nakamura","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.0022-202X.2005.10130_5.x","article-title":"The functional relevance of the type 1 cytokines IFN-gamma and IL-2 in alopecia areata of C3H\/HeJ mice","volume":"10","author":"Zoller","year":"2005","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2133.2006.07377.x","article-title":"Interferon-gamma-deficient mice are resistant to the development of alopecia areata","volume":"155","author":"McElwee","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s00403-002-0354-7","article-title":"Strong expression of CD40, CD54 and HLA-DR antigen and lack of evidence for direct cellular cytotoxicity are unique immunohistopathological features in alopecia areata","volume":"294","author":"Aiba","year":"2003","journal-title":"Arch. Dermatol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/exd.12489","article-title":"The role of cytokines and chemokines in the T-cell-mediated autoimmune process in alopecia areata","volume":"23","author":"Ito","year":"2014","journal-title":"Exp. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jdcr.2018.11.007","article-title":"Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab","volume":"5","author":"Smogorzewski","year":"2019","journal-title":"JAAD. Case. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.18176\/jiaci.0301","article-title":"Alopecia Areata in Severe Atopic Dermatitis Treated with Dupilumab","volume":"28","author":"Rial","year":"2018","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jdcr.2018.10.010","article-title":"Drug-induced alopecia after dupilumab therapy","volume":"5","author":"Flanagan","year":"2019","journal-title":"JAAD. Case. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1111\/1346-8138.14880","article-title":"Case of alopecia areata during dupilumab treatment for atopic dermatitis","volume":"46","author":"Kanda","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_15","first-page":"e41","article-title":"Dermatitis and alopecia in a patient treated with dupilumab: A new adverse effect?","volume":"44","author":"Suarez","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2340\/00015555-3183","article-title":"Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report","volume":"99","author":"Uchida","year":"2019","journal-title":"Acta. Derm. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/all.13346","article-title":"Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/intimm\/dxy015","article-title":"Multipolarity of cytokine axes in the pathogenesis of atopic dermatitis in terms of age, race, species, disease stage and biomarkers","volume":"30","author":"Nomura","year":"2018","journal-title":"Int. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaci.2017.06.005","article-title":"Advances in atopic dermatitis and urticarial in 2016","volume":"140","author":"Honda","year":"2017","journal-title":"J. Allergy. Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.18176\/jiaci.0519","article-title":"A multicentric study on prevalence of clinical patterns and clinical phenotypes in adult atopic dermatitis","volume":"30","author":"Nettis","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2010.02.008","article-title":"Extrinsic and intrinsic types of atopic dermatitis","volume":"58","author":"Tokura","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e12787","DOI":"10.1111\/dth.12787","article-title":"What\u2019s new in the treatment of atopic dermatitis?","volume":"32","author":"Dattola","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17512433.2018.1449642","article-title":"Dupilumab for treatment of atopic dermatitis","volume":"11","author":"Seegraber","year":"2018","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"s28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: A review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.alit.2020.01.002","article-title":"Dupilumab: Basic aspects and applications to allergic diseases","volume":"69","author":"Matsunaga","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_26","first-page":"534","article-title":"Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata","volume":"179","author":"Darrigade","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e13023","DOI":"10.1111\/dth.13023","article-title":"Dupilumab and alopecia: A Janus effect","volume":"32","author":"Patruno","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jamadermatol.2018.2976","article-title":"Hair Regrowth in a Patient With Long-standing Alopecia Totalis and Atopic Dermatitis Treated With Dupilumab","volume":"154","author":"Penzi","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jdcr.2018.11.006","article-title":"Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis","volume":"5","author":"Alniemi","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_30","first-page":"139","article-title":"Alopecia Universalis and Atopic Dermatitis Improvement with Dupilumab: Demonstration of a Shared Pathophysiology and Clinical Efficacy","volume":"17","author":"Dobkin","year":"2019","journal-title":"Skinmed"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archderm.139.12.1555","article-title":"Histopathologic features of alopecia areata: A new look","volume":"139","author":"Whiting","year":"2003","journal-title":"Arch. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-0560.2010.01640.x","article-title":"\u2018Follicular Swiss cheese\u2019 pattern--another histopathologic clue to alopecia areata","volume":"38","author":"Muller","year":"2011","journal-title":"J. Cutan. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jdcr.2017.11.020","article-title":"Alopecia areata after dupilumab for atopic dermatitis","volume":"4","author":"Mitchell","year":"2018","journal-title":"JAAD Case Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jdcr.2019.03.019","article-title":"Alopecia areata in 2 patients treated with dupilumab: New onset and worsening","volume":"5","author":"Chung","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/DER.0000000000000458","article-title":"Alopecia Areata after Treatment with Dupilumab","volume":"30","author":"Yazdanyar","year":"2019","journal-title":"Dermatitis"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Carnicle, J.M., Hendricks, A.J., and Shi, V.Y. (2019). Reactivation of Alopecia Areata after Dupilumab Therapy for Atopic Dermatitis. Dermatitis.","DOI":"10.1097\/DER.0000000000000512"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jdermsci.2012.12.003","article-title":"CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase","volume":"69","author":"Ito","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09546634.2019.1689227","article-title":"Dupilumab use in dermatologic conditions beyond atopic dermatitis\u2014A systemic review","volume":"32","author":"Hendricks","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-020-01293-0","article-title":"New and Emerging Therapies for Alopecia Areata","volume":"80","author":"Pourang","year":"2020","journal-title":"Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2016.08.047","article-title":"Autoimmune diseases in adults with atopic dermatitis","volume":"76","author":"Andersen","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000499080","article-title":"Dupilumab and Alopecia: Causative or Therapeutic?","volume":"235","author":"Hendricks","year":"2019","journal-title":"Dermatology"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"McKenzie, P.L., and Castelo-Soccio, L. (2021). Dupilumab Therapy for Alopecia Areata in Pediatric Patients with Concomitant Atopic Dermatitis. J. Am. Acad. Dermatol., 20.","DOI":"10.1016\/j.jaad.2021.01.046"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamadermatol.2018.2312","article-title":"Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: A systematic review and meta-analysis","volume":"154","author":"Lee","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.4049\/jimmunol.159.5.2484","article-title":"Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile","volume":"159","author":"Kitagaki","year":"1997","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000246337","article-title":"Topical immunotherapy in alopecia areata: Anamnestic and clinical criteria of prognostic significance","volume":"192","author":"Weise","year":"1996","journal-title":"Dermatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/exd.13758","article-title":"Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata","volume":"29","author":"Gong","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2133.2001.04398.x","article-title":"Impaired responses of peripheral blood mononuclear cells to T-cell stimulants in alopecia areata patients with a poor response to topical immunotherapy","volume":"145","author":"Yoshino","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2133.2004.05696.x","article-title":"Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme","volume":"150","author":"Barbier","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2618\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:33:23Z","timestamp":1760160803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["ijms22052618"],"URL":"https:\/\/doi.org\/10.3390\/ijms22052618","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]}}}